BRIMONIST-TM
Overview:
Brimonist TM is a dual-action ophthalmic solution formulated with Brimonidine Tartrate (2.0 mg) and Timolol, designed to effectively reduce intraocular pressure (IOP) in patients with glaucoma and ocular hypertension. By combining an alpha-2 adrenergic agonist (Brimonidine) and a beta-blocker (Timolol), Brimonist TM provides enhanced IOP control, reducing the risk of optic nerve damage and vision loss
- Class
- Dosage
- Indications
- Mechanism of action
Anti-glaucoma Agent
Adults & Elderly: 1 drop in the affected eye(s) twice daily (morning & evening) or as prescribed by an ophthalmologist.
- Primary Open-Angle Glaucoma – Reduces elevated intraocular pressure.
- Ocular Hypertension – Lowers high eye pressure to prevent optic nerve damage.
- Combination Therapy – Suitable when monotherapy is insufficient.
Brimonidine Tartrate reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow. Timolol, a non-selective beta-blocker, further reduces IOP by inhibiting aqueous humor secretion in the ciliary body. Together, these agents work synergistically to lower IOP effectively, preventing optic nerve damage and slowing the progression of glaucoma.
